Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMALMGH)

• Drug Name: 3-demethoxy-3-D-mannopyranosylaminothiocolchicine Drug Info
• Synonyms: CHEMBL214305

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 16081752
  TTD Drug ID: DMALMGH

Molecule-Related Drug Atlas

Drug(s) Targeting GABA(A) receptor gamma-2 (GABRG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[2]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[1]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[3]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[1]
ELTANOLONE	DM38CIV	Premenstrual syndrome	GA34.40	Discontinued in Phase 3	[2]
U-78875	DM2WOPX	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[4]
CGS-9896	DM39PQI	N. A.	N. A.	Terminated	[5]
CGS-17867A	DMMZJY3	Alcohol dependence	6C40.2	Terminated	[6]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[7]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Strychnine-binding glycine receptor (GLRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[1]
D-Serine	DM3YH4I	N. A.	N. A.	Phase 4	[9]
GINKOLIDE B	DMLIM7B	Sepsis	1G40-1G41	Terminated	[10]
3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	DME8VPC	Discovery agent	N.A.	Investigative	[1]
3-demethoxy-3-D-xylopyranosylaminothiocolchicine	DMXFVD1	Discovery agent	N.A.	Investigative	[1]
3-demethoxy-3-L-fucopyranosylaminothiocolchicine	DM4ERYF	Discovery agent	N.A.	Investigative	[1]
3-demethoxy-3D-glucopyranosylaminothiocolchicine	DMID7TC	Discovery agent	N.A.	Investigative	[1]
GINKGOLIDE A	DMKZJ7T	Discovery agent	N.A.	Investigative	[10]
Ginkgolide J	DMUOMP1	Discovery agent	N.A.	Investigative	[10]
Ginkgolide C	DMVN374	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting GABA(A) receptor alpha-1 (GABRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[11]
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[12]
Methoxyflurane	DML0RAE	Anaesthesia	9A78.6	Approved	[11]
Nitrazepam	DMEGIQ6	Epilepsy	8A60-8A68	Approved	[11]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[2]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[11]
Hexobarbital	DMQ314B	Anaesthesia	9A78.6	Approved	[11]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[1]
Meprobamate	DMHM93Y	Anxiety		Approved	[11]
Zaleplon	DMGFWSM	Insomnia	7A00-7A0Z	Approved	[13]

Drug(s) Targeting Glycine receptor (GlyR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[1]
ZD-9379	DM3KYO4	Cerebrovascular ischaemia	8B1Z	Phase 1	[14]
UK-240455	DMSCXB7	Nerve injury	ND56.4	Phase 1	[15]
MDL-27531	DMC60S8	Epilepsy	8A60-8A68	Phase 1	[16]
Gavestinel	DM8IL1U	Nerve injury	ND56.4	Discontinued in Phase 2	[17]
GV-196771	DMFN21T	Migraine	8A80	Discontinued in Phase 2	[18]
GW 468816	DMQ92WF	Tobacco dependence	6C4A.2	Discontinued in Phase 2	[19]
M-241247	DMIY51U	Cerebrovascular ischaemia	8B1Z	Terminated	[20]
GINKOLIDE B	DMLIM7B	Sepsis	1G40-1G41	Terminated	[10]
3-demethoxy-3-D-lyxopyranosylaminothiocolchicine	DME8VPC	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[11]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[21]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[1]
Clonazepam	DMTO13J	Absence epilepsy		Approved	[22]
Piperazine	DMTY9LU	Ascariasis	1F62	Approved	[23]
Alpidem	DMN7Y9K	Anxiety disorder	6B00-6B0Z	Approved	[24]
Moxidectin	DMYGHX5	Onchocerciasis	1F6A	Approved	[25]
DP-VPA	DMGOXPQ	Bipolar disorder	6A60	Approved	[26]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[21]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[3]

Drug(s) Targeting GABA(A) receptor beta-2 (GABRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[2]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[1]
Ethchlorvynol	DM53IP1	Insomnia	7A00-7A0Z	Approved	[11]
ZK-93423	DMFWMKZ	Epileptic seizures	8A61-8A6Z	Phase 3	[3]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[1]
ELTANOLONE	DM38CIV	Premenstrual syndrome	GA34.40	Discontinued in Phase 3	[2]
U-78875	DM2WOPX	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[27]
CGS-9896	DM39PQI	N. A.	N. A.	Terminated	[5]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[28]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-1 (GABRA1)	TT1MPAY	GBRA1_HUMAN	Inhibitor	[1]
GABA(A) receptor beta-2 (GABRB2)	TTZA1NY	GBRB2_HUMAN	Inhibitor	[1]
GABA(A) receptor gamma-2 (GABRG2)	TT06RH5	GBRG2_HUMAN	Inhibitor	[1]
Gamma-aminobutyric acid receptor (GAR)	TTNJYV2	NOUNIPROTAC	Inhibitor	[1]
Glycine receptor (GlyR)	TTZ8EM9	GLRA1_HUMAN; GLRA2_HUMAN; GLRA3_HUMAN; GLRA4_HUMAN; GLRB_HUMAN	Inhibitor	[1]
Strychnine-binding glycine receptor (GLRA1)	TTF45NW	GLRA1_HUMAN	Inhibitor	[1]

References

• [1] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [2] Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
• [3] Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
• [4] 3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36.
• [5] Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
• [6] 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 414).
• [8] Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
• [9] Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
• [10] Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7.
• [11] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [12] Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [14] Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26.
• [15] UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001 Dec;2(12):1737-9.
• [16] MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neurosci Lett. 1992 Nov 23;147(1):101-5.
• [17] Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial.GAIN International Investigators.Lancet.2000 Jun 3;355(9219):1949-54.
• [18] First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol. 1999 Jun;39(6):560-6.
• [19] A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.J Clin Psychopharmacol.2011 Oct;31(5):597-602.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)
• [21] Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
• [22] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [23] Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
• [24] Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
• [25] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [26] DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
• [27] High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 411).